Shanghai Pharmaceuticals (SHA:601607, HKG:2607) has been authorized to market Pregabalin capsules in Thailand after its unit, SHP Thailand, received a drug registration certificate from the country's drug administration, according to a Shanghai bourse disclosure on Friday.

The drug is primarily used for the treatment of postherpetic neuralgia, diabetic peripheral neuropathic pain, fibromyalgia, and neuropathic pain associated with spinal cord injury, as well as an adjunctive treatment for epilepsy, the Chinese pharmaceutical company said.